BRUIN CLL-314: Pirtobrutinib demonstrates noninferior ORR versus ibrutinib in the first head-to-head trial in BTKi-naïve patients with CLL/SLL

ASH 2025

Leukemia

LBA-3: BRUIN CLL-313: Pirtobrutinib is superior to bendamustine plus rituximab in treatment-naïve CLL/SLL

Leukemia

Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)

J Clin Oncol

Sharman JP, Munir T, Grosicki S, Roeker LE, Burke JM, Chen CI, Grzasko N, Follows G, Mátrai Z, Sanna A, Qiu L, Feng R, Hua VM, Jurczak W, Ritgen M, Yi S, Bosch F, Coombs CC, Bao K, Patel V, Liu B, Compte L, Guntur A, Wang DY, Hill M, Leow CC, Ghia P, Barr PM

doi: 10.1200/JCO-25-00166

Leukemia

Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL

Blood

Burger JA, Barr PM, Robak T Prof, Owen C, Tedeschi A, Sarma A, Patten PE, Grosicki S, McCarthy H Dr, Offner F, Szafer Glusman E, Zhou C, Szoke A, Neumayr L, Dean JP, Ghia P, Kipps T

doi: 10.1182/blood.2024028205

Lymphoma

Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2/3 superiority trial

Lancet

Lewis DJ, Jerkeman M, Sorrell L, Wright D, Glimelius I, Poulsen CB, Pasanen A, Rawstron A, Wader KF, Morley N, Burton C, Davies AJ, Lagerlöf I, Dalal S, De Tute R, McNamara C, Crosbie N, Toldbod HE, Sanders J, Allgar V, Aroori S, Warner M, Scully C, Wainman B, Christensen JH, Riise J, Sonnevi K, Bishton MJ, Eyre TA, Rule S, ENRICH investigators

doi: 10.1016/S0140-6736(25)01432-1

Gynecologic Cancer

Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor α-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trial

Lancet Oncol

Van Gorp T, Moore KN, Konecny GE, Leary A, García-García Y, Banerjee S, Lorusso D, Lee JY, Moroney JW, Caruso G, Klasa-Mazurkiewicz D, Tromp J, Martin LP, Breuer S, Leath CA 3rd, Cibula D, Weroha SJ, Estévez-García P, O'Malley DM, Miller RE, Coffman L, Scandurra G, Berton D, Li L, Zagadailov E, Diver EJ, Trédan O, Hilpert F

doi: 10.1016/S1470-2045(25)00021-X

ASH 2025

Lymphoma

BRUIN: Durable benefits with pirtobrutinib in patients with R/R Waldenström macroglobulinemia

Lymphoma

Noninvasive genotyping and early disease dynamics demonstrate the efficacy of ibrutinib in combination with immunochemotherapy in patients with mantle cell lymphoma treated in the TRIANGLE trial

Leukemia

Khouja M, Genuardi E, Ferrero S, Laqua A, Alessandria B, Verhagen OJHM, Homburg CHE, Sanz RG, Medina Herrera A, van der Velden VHJ, da Silva MG, Gameiro P, Doorduijn J, Giné E, Visco C, Brüggemann M, Baldus CD, Ladetto M, Schmidt C, Dreyling M, Jiang L, Hoster E, Darzentas N, Pal K, Chitadze G, Stewart JP, Gonzalez D, Pott C, European MCL Network

doi: 10.1038/s41375-025-02787-0

Lung, Respiratory and Thoracic Cancer

Comparative analysis of first-line treatment in NSCLC including unresectable stage III (IIIB/IIIC) and stage IV with low PD-L1 expression: Clinical trial eligible versus ineligible patients

Lung Cancer

Hata T, Yamada T, Goto Y, Amano A, Negi Y, Watanabe S, Furuya N, Oba T, Ikoma T, Nakao A, Tanimura K, Taniguchi H, Yoshimura A, Fukui T, Murata D, Kaira K, Shiotsu S, Hibino M, Okada A, Chihara Y, Kawachi H, Kijima T, Takayama K

doi: 10.1016/j.lungcan.2025.108104

Genitourinary Cancer

Final overall survival and safety analyses of the phase 3 PSMAfore trial of [(177)Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer

Ann Oncol

Fizazi K, Chi KN, Shore ND, Herrmann K, de Bono JS, Castellano D, Piulats JM, Fléchon A, Wei XX, Mahammedi H, Roubaud G, Fleming M, Haas T, Ghebremariam S, Kreisl TN, Rajagopalan S, Sartor O, Morris MJ, PSMAfore Investigators

doi: 10.1016/j.annonc.2025.07.003

Related content

LBA-3: BRUIN CLL-313: Pirtobrutinib is superior to bendamustine plus rituximab in treatment-naïve CLL/SLL

Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)

Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL

Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2/3 superiority trial

Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor α-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trial

BRUIN: Durable benefits with pirtobrutinib in patients with R/R Waldenström macroglobulinemia

Noninvasive genotyping and early disease dynamics demonstrate the efficacy of ibrutinib in combination with immunochemotherapy in patients with mantle cell lymphoma treated in the TRIANGLE trial

Comparative analysis of first-line treatment in NSCLC including unresectable stage III (IIIB/IIIC) and stage IV with low PD-L1 expression: Clinical trial eligible versus ineligible patients

Final overall survival and safety analyses of the phase 3 PSMAfore trial of [(177)Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer